David Smith Purchases Shares of Codexis, Inc.

David Smith recently purchased 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS) on June 17, 2026. This insider buying activity was reported with no planned transaction details and at a value of $0.0 per share. Codexis shares were trading at $2.57 at the time.

Insider Buying and Selling at Codexis, Inc.

Several insiders, including David Smith, Christos Richards, Parker Stewart, and others, each acquired 66,350 shares of Codexis on June 17, 2026. These transactions were not part of a pre-planned trading scheme and were reported at a value of $0.0 per share.

Other Institutional Activity in Codexis, Inc.

Aberdeen Group PLC increased its holdings in Codexis by 713,870 shares, ending with 8,680,368 shares valued at about $14.15 million. BlackRock, Inc. trimmed its position by 366,967 shares, leaving it with 7,028,773 shares worth approximately $11.46 million. Opaleye Management Inc. made a small reduction of 4,738 shares, holding 6,785,000 shares valued at $11.06 million. Meanwhile, Nantahala Capital Management, LLC added 133,444 shares, bringing its total to 4,123,613 shares valued at $6.72 million. Millennium Management LLC significantly boosted its holdings by 862,938 shares, now holding 3,998,130 shares worth about $6.52 million.

Codexis, Inc. Stock Snapshot

Shares of Codexis, Inc. traded near $2.57 on the NasdaqGS. The company has a market capitalization of $233.6 million and a forward P/E ratio of -6.95, indicating it isn't currently profitable. Codexis has a beta of 2.478, suggesting higher volatility compared to the market. The stock's 52-week range is between $0.96 and $3.87, with a 50-day moving average of $2.569 and a 200-day moving average of $2.0225. Codexis maintains a current ratio of 5.364 and a quick ratio of 4.927, with a debt-to-equity ratio of 168.624.

Recent Earnings

Codexis reported revenue of $78.09 million, with a modest growth rate of 1.021. The company posted a net margin of -40.965% and a return on equity of -68.897%. Its next earnings report is expected on August 12, 2026.

Analysts Set New Price Targets

On August 29, 2024, Cantor Fitzgerald reiterated a 'buy' rating for Codexis with a price target of $11.0. Stifel Nicolaus maintained their 'buy' rating with a $5.0 target on May 20, 2024. Benchmark Co. also maintained a 'buy' rating, setting a target of $9.0 on May 3, 2024. Piper Sandler reiterated a 'buy' rating with a $10.0 target on April 26, 2024. The consensus recommendation for Codexis is a 'buy', with a target mean price of $6.58 based on six analyst opinions.

About Codexis, Inc.

Codexis, Inc. is a biotechnology company based in Redwood City, California, specializing in enzyme development and manufacturing solutions for therapeutics. Utilizing its CodeEvolver technology platform, Codexis creates innovative enzymes for various applications, including RNAi therapeutics. The company collaborates with partners like Aldevron and Pfizer to advance its technologies across multiple regions including North America, Europe, and Asia. Dr. Alison Moore serves as the CEO, leading a team of approximately 146 employees.

Bottom Line

David Smith's recent purchase of Codexis shares highlights ongoing insider interest in the company. Codexis continues to develop its enzyme technology for therapeutic applications, though it currently operates at a loss. Investors monitor insider transactions and analyst ratings as potential indicators of future performance, but it's important to remember that these filings report past actions and may not reflect current positions.